Novo Nordisk's Q1 in four words: Pills, pricing, payments and pressure
A million patients with obesity are already taking Novo Nordisk’s Wegovy pill, CEO Mike Doustdar said Wednesday, despite the market entry of Lilly’s Foundayo. N...
A million patients with obesity are already taking Novo Nordisk’s Wegovy pill, CEO Mike Doustdar said Wednesday, despite the market entry of Lilly’s Foundayo. Novo's pill had sales of 2.3 billion Danish ...